Dipiperidines as a new class of anti-TB drug

Award Information
Agency:
Department of Health and Human Services
Amount:
$299,475.00
Program:
SBIR
Contract:
1R43AI060250-01
Solitcitation Year:
2004
Solicitation Number:
PHS2004-2
Branch:
N/A
Award Year:
2004
Phase:
Phase I
Agency Tracking Number:
AI060250
Solicitation Topic Code:
N/A
Small Business Information
SEQUELLA, INC.
SEQUELLA, INC., 9610 MEDICAL CENTER DR, STE 200, ROCKVILLE, MD, 20850
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 MARINA Protopopova
 (301) 217-3832
 MARINAPROTOPOPOVA@SEQUELLA.COM
Business Contact
Phone: (301) 762-7776
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The overall aim of this application is to characterize a new class of drugs to treat tuberculosis (TB) that are structurally unrelated to any existing anti-TB drugs. Three years ago, Sequella received a Challenge gran

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government